503.82
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché VRTX Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$501.15
Aprire:
$501.45
Volume 24 ore:
336.77K
Relative Volume:
0.23
Capitalizzazione di mercato:
$127.64B
Reddito:
$11.02B
Utile/perdita netta:
$-535.60M
Rapporto P/E:
-229.01
EPS:
-2.2
Flusso di cassa netto:
$-978.00M
1 W Prestazione:
+1.56%
1M Prestazione:
+6.24%
6M Prestazione:
+0.87%
1 anno Prestazione:
+25.72%
Vertex Pharmaceuticals Inc Stock (VRTX) Company Profile
Nome
Vertex Pharmaceuticals Inc
Settore
Industria
Telefono
(617) 341-6393
Indirizzo
50 NORTHERN AVENUE, BOSTON, MA
Confronta VRTX con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
VRTX
Vertex Pharmaceuticals Inc
|
504.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
606.69 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ARGX
Argen X Se Adr
|
655.87 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
268.03 | 32.98B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
252.16 | 26.89B | 3.81B | -644.79M | -669.77M | -6.24 |
Vertex Pharmaceuticals Inc Stock (VRTX) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-04-22 | Ripresa | Cantor Fitzgerald | Overweight |
2025-02-12 | Aggiornamento | Canaccord Genuity | Sell → Hold |
2025-02-11 | Aggiornamento | Canaccord Genuity | Sell → Hold |
2025-01-30 | Downgrade | Wells Fargo | Overweight → Equal Weight |
2024-12-20 | Reiterato | H.C. Wainwright | Buy |
2024-12-19 | Downgrade | Oppenheimer | Outperform → Perform |
2024-12-09 | Aggiornamento | Jefferies | Hold → Buy |
2024-11-14 | Iniziato | Citigroup | Buy |
2024-10-16 | Iniziato | Scotiabank | Sector Perform |
2024-10-10 | Ripresa | Raymond James | Mkt Perform |
2024-08-05 | Downgrade | Barclays | Overweight → Equal Weight |
2024-06-27 | Iniziato | Redburn Atlantic | Buy |
2024-04-11 | Aggiornamento | Evercore ISI | In-line → Outperform |
2024-02-15 | Iniziato | Wolfe Research | Outperform |
2024-02-06 | Downgrade | Evercore ISI | Outperform → In-line |
2024-02-02 | Downgrade | Bernstein | Outperform → Mkt Perform |
2024-01-31 | Downgrade | Maxim Group | Buy → Hold |
2024-01-31 | Downgrade | Robert W. Baird | Neutral → Underperform |
2024-01-24 | Downgrade | Canaccord Genuity | Hold → Sell |
2023-12-14 | Reiterato | RBC Capital Mkts | Sector Perform |
2023-05-30 | Iniziato | William Blair | Outperform |
2023-05-04 | Ripresa | Piper Sandler | Overweight |
2023-03-21 | Iniziato | Bernstein | Outperform |
2023-01-18 | Iniziato | Canaccord Genuity | Hold |
2023-01-17 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
2022-12-19 | Downgrade | Jefferies | Buy → Hold |
2022-07-13 | Iniziato | Cantor Fitzgerald | Overweight |
2022-06-01 | Aggiornamento | Maxim Group | Hold → Buy |
2022-05-23 | Iniziato | SVB Leerink | Mkt Perform |
2022-05-06 | Downgrade | Robert W. Baird | Outperform → Neutral |
2022-05-03 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
2022-02-03 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
2022-01-27 | Reiterato | JP Morgan | Overweight |
2022-01-27 | Reiterato | Morgan Stanley | Underweight |
2022-01-27 | Reiterato | RBC Capital Mkts | Outperform |
2022-01-27 | Reiterato | Stifel | Hold |
2022-01-27 | Reiterato | Wolfe Research | Outperform |
2022-01-20 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
2021-12-09 | Iniziato | Wells Fargo | Overweight |
2021-11-19 | Iniziato | BMO Capital Markets | Market Perform |
2021-11-19 | Downgrade | Piper Sandler | Overweight → Neutral |
2021-09-09 | Downgrade | Stifel | Buy → Hold |
2021-09-07 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
2021-07-20 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
2021-07-19 | Ripresa | Wolfe Research | Outperform |
2021-07-01 | Iniziato | Raymond James | Mkt Perform |
2021-06-11 | Downgrade | Daiwa Securities | Outperform → Neutral |
2021-02-23 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
2021-02-02 | Reiterato | H.C. Wainwright | Buy |
2020-12-30 | Iniziato | Daiwa Securities | Outperform |
2020-11-30 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
2020-11-20 | Iniziato | Bernstein | Outperform |
2020-10-28 | Iniziato | UBS | Buy |
2020-07-31 | Reiterato | H.C. Wainwright | Buy |
2020-07-08 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
2020-04-30 | Reiterato | H.C. Wainwright | Buy |
2020-04-28 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
2020-03-04 | Iniziato | Barclays | Overweight |
2020-01-31 | Downgrade | Robert W. Baird | Outperform → Neutral |
2019-11-19 | Aggiornamento | Guggenheim | Neutral → Buy |
2019-11-12 | Iniziato | SunTrust | Buy |
2019-10-17 | Ripresa | BofA/Merrill | Buy |
2019-09-03 | Aggiornamento | Goldman | Neutral → Buy |
2019-08-01 | Downgrade | Needham | Buy → Hold |
2019-05-23 | Ripresa | Citigroup | Buy |
2019-05-21 | Iniziato | Credit Suisse | Outperform |
2019-04-12 | Iniziato | Evercore ISI | In-line |
2019-03-26 | Aggiornamento | William Blair | Mkt Perform → Outperform |
2019-03-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
2019-02-06 | Downgrade | Maxim Group | Buy → Hold |
Mostra tutto
Vertex Pharmaceuticals Inc Borsa (VRTX) Ultime notizie
Vertex Abandons AAV as Gene Therapy Space Weathers Difficulties - BioSpace
3 No-Brainer Stocks to Buy in May - The Motley Fool
Gilead and Vertex Pharma named among biotech’s tariff safe havens - MSN
How Will Vertex Pharmaceuticals Stock React To Its Upcoming Earnings? - Nasdaq
Vertex Pharmaceuticals (VRTX) Earnings Preview: What to Expect - GuruFocus
Vertex discontinues AAV research for gene therapies - Fierce Biotech
As Journavx rollout begins, Vertex kicks off unbranded pain campaign with NFL alum Alex Smith - Fierce Pharma
Vertex Pharmaceuticals (VRTX) Outperforms Broader Market: What You Need to Know - Yahoo Finance
Final Trades: Berkshire Hathaway, Vertex Pharma, S&P Global and CME Group - MSN
What Analyst Projections for Key Metrics Reveal About Vertex (VRTX) Q1 Earnings - Nasdaq
Vertex Gears Up to Report Q1 Earnings: Is a Beat in the Cards? - Yahoo Finance
Vertex Pharmaceuticals (VRTX) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release - Yahoo Finance
European regulators recommend new drugs from Vertex, Amgen and Jazz - Endpoints News
, a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis - Business Wire
Press Release Distribution & PR Platform - ACCESS Newswire
US Health Secretary Reportedly Says 35 States to Join Pilot Program for Sickle Cell Disease Gene Therapies - marketscreener.com
EMA Backs Vertex Pharmaceuticals' (VRTX) Alyftrek for Cystic Fib - GuruFocus
Vertex’s Alyftrek For CF Among Six Orphans On Track For Pan-EU Approval - insights.citeline.com
Vertex Pharmaceuticals Stock (VRTX) Trending as Q1 Earnings Approach - TipRanks
Vertex Pharmaceuticals (VRTX) Advances But Underperforms Market: Key Facts - Yahoo Finance
Why Vertex Pharmaceuticals Was Such a Healthy Stock on Tuesday - MSN
Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It - MSN
Vertex Pharmaceuticals’ Q1 2025 Earnings: What to Expect - Nasdaq
Vertex Pharmaceuticals’ Q1 2025 Earnings: What To Expect - Barchart.com
Eli Lilly, Vertex, AbbVie and More Pharma Stocks to Own as Tariffs Loom - MSN
Eli Lilly, Vertex, AbbVie, and More Pharma Stocks to Own as Tariffs Loom - Barron's
Vertex Pharmaceuticals (VRTX) Gains Favor with Increased Price T - GuruFocus
Expert Outlook: Vertex Pharmaceuticals Through The Eyes Of 18 Analysts - Benzinga
Vertex Pharmaceuticals (VRTX) Gains Favor with Increased Price Target | VRTX Stock News - GuruFocus
ToolGen sues Vertex over alleged unlicensed use of CRISPR tech in gene therapy - koreabiomed.com
Vertex Has A Lot Riding On Alyftrek, Journavx — And Investors Are Watching Closely - Benzinga
Vertex Pharmaceuticals (NasdaqGS:VRTX) Faces UK Patent Lawsuit Over Groundbreaking CASGEVY Therapy - simplywall.st
ToolGen Files Patent Infringement Lawsuit Against Vertex in the United Kingdom - Longview News-Journal
Lobbying Update: $1,600,000 of VERTEX PHARMACEUTICALS INCORPORATED lobbying was just disclosed - Nasdaq
Reshma Kewalramani Among TIME’s 100 Most Influential People Of 2025 - IndiaWest
Reshma Kewalramani among 2025 Time 100 most influential people - The American Bazaar
Peering Into Vertex Pharmaceuticals's Recent Short Interest - Benzinga
Reshma Kewalramani named among Time magazine's 100 most influential people - Firstpost
Vertex’s Attempt to Redefine AKS Falls Short: Key Insights for Pharma Manufacturers - ArentFox Schiff
Goldman Sachs Adjusts Price Target on Vertex Pharmaceuticals to $617 From $615, Maintains Buy Rating - marketscreener.com
Vertex Researcher, Paul Negulescu Ph.D., Receives the 2025 Canada Gairdner International Award for Pioneering Research and Discovery of Medicines for Cystic Fibrosis - BioSpace
Vertex Pharmaceuticals (VRTX) Celebrated for Groundbreaking CF R - GuruFocus
Could CRISPR Therapeutics Become the Next Vertex Pharmaceuticals? - AOL.com
Lobbying Update: $20,000 of VERTEX PHARMACEUTICALS INCORPORATED lobbying was just disclosed - Nasdaq
Vertex Pharmaceuticals Inc Azioni (VRTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):